Optimal Medication for Severe Osteoporosis with Prior Stroke History

Primary Treatment Recommendation

The American College of Physicians provides a strong recommendation based on high-quality evidence for fracture reduction with oral bisphosphonates, such as alendronate 70 mg weekly or risedronate 35 mg weekly, but oral administration may be problematic post-stroke 1

The American College of Physicians recommends intravenous zoledronic acid 5 mg annually as an alternative treatment option, particularly appropriate for stroke patients as it avoids oral administration challenges 1

If denosumab is ever stopped, there is an increased risk of multiple vertebral fractures due to rebound bone turnover, and transition to a bisphosphonate beginning 6-7 months after the last denosumab dose is necessary to prevent this complication 2

Calcium supplementation of 1,000-1,200 mg daily is recommended for patients with severe osteoporosis 4
Vitamin D supplementation of 600-800 IU daily, with a target serum level >30-50 ng/mL, is recommended for patients with severe osteoporosis 4
Weight-bearing exercise as tolerated post-stroke is recommended for patients with severe osteoporosis 3

The American College of Physicians recommends continuing denosumab for 5 years initially, without routine BMD monitoring during the initial 5-year treatment period 1
After 5 years, reassessing fracture risk to determine if continued therapy is warranted is recommended 3

The American College of Rheumatology conditionally recommends against romosozumab due to increased risk of myocardial infarction, stroke, and death—particularly problematic in a patient with prior stroke history 4
The American College of Physicians strongly recommends against raloxifene due to increased risk of thromboembolic events, pulmonary embolism, and fatal stroke 1
The American College of Rheumatology conditionally recommends teriparatide (PTH/PTHrP) over anti-resorptives in very high-risk patients, but it requires daily injections and subsequent anti-resorptive therapy, making it less practical than denosumab for this patient 4